Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
The National Diabetes Statistics Report is a periodic publication that provides updated statistics.
Original title: “National Diabetes Statistics Report”
Original title: “Electronic Health Records (EHRs)”
CDC’s National Healthcare Safety Network is the nation’s most widely used healthcare-associated infection tracking system.
Original title: “Point of Care”
Find information about PHAP host site Webinars including steps on how to apply and more.
Original title: “Host Site Informational Webinars”
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval." When finalized, this guidance will provide recommendations to sponsors about using minimal residual disease (MRD) and complete response (CR) in multiple myeloma as primary endpoints in trials evaluating drug and biological products intended to treat pat
Original title: “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints To Support Accelerated Approval; Draft Guidance for Industry; Availability”
The Food and Drug Administration (FDA or the Agency) is announcing the issuance of Emergency Use Authorizations (EUA) (the Authorizations) for certain medical devices related to Coronavirus Disease 2019 (COVID-19). FDA has issued the Authorizations listed in this document under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Under the FD&C Act, FDA is required to publish in the Federal Register a notice of each authorization, and each termination or revocation of an authorization, and an ex
Original title: “Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability”
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "M4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is intended to establish a globally harmonized framework to organizing and presenting
Original title: “M4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality; International Council for Harmonisation; Draft Guidance for Industry; Availability”
The Health Information Technology Advisory Committee (HITAC) was established in accordance with the 21st Century Cures Act and the Federal Advisory Committee Act. The HITAC, among other things, identifies priorities for standards adoption and makes recommendations to the Assistant Secretary for Technology Policy/National Coordinator for Health Information Technology. The HITAC will hold public meetings throughout 2026. See list of public meetings below.
Original title: “Health Information Technology Advisory Committee Schedule of Meetings”
The Administration for Children and Families (ACF) is requesting a 3-year extension of the ACF-204: Annual Temporary Assistance for Needy Families (TANF) and State Maintenance-of-Effort (MOE) Report (Office of Management and Budget (OMB) #: 0970-0248, expiration March 31, 2026). There are no substantive changes requested to the form but instructions have been updated and burden estimates adjusted.
Original title: “Proposed Information Collection Activity; Annual Report on Temporary Assistance for Needy Families Programs and State Maintenance-of-Effort Programs-ACF-204 (Annual TANF and MOE Report)”
Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”
Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”
Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”
EMA has published an overview of its key recommendations of 2025 regarding the authorisation and safety monitoring of veterinary medicines.In 2025, EMA recommended 30…
Original title: “Veterinary medicines in 2025”
At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines:…, Agenda Agenda of the PRAC meeting 12 - 15 January 2026Draft…, PRAC statistics: January 2026 , PRAC statistics: January 2026 Engl
Original title: “Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 12 - 15 January 2026”
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Poison Center Collaborations for Public Health Emergencies (PCCPHE). PCCPHE creates
Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”
This notice provides an update of the Department of Health and Human Services (HHS) poverty guidelines to account for last calendar year's increase in prices as measured by the Consumer Price Index.
Original title: “Annual Update of the HHS Poverty Guidelines”
Referred to the House Committee on Energy and Commerce.
Original title: “HR 7118: Genomic Answers for Children’s Health Act of 2026”
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Maritime Activity Illness and Death Reporting. This data collection is designed to e
Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”
Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”
EMA and the U.S. Food and Drug Administration (FDA) have jointly identified ten principles for good artificial intelligence (AI) practice in the medicines lifecycle.The…, "The guiding principles of good AI practice in drug development are a first step of a renewed EU-US cooperation in the field of novel medical technologies. The…, The use of AI technologies across the medicines lifecycle has increased significantly in recent years. As emphasised in the European Commission’s Biotech Act
Original title: “EMA and FDA set common principles for AI in medicine development”